The use of GLP-1 receptor agonists, such as Ozempic, has surged in India, prompting concerns over their misuse as cosmetic weight-loss solutions rather than for treating medical conditions like Type 2 diabetes. Dr. Vimal Pahuja, an expert in metabolic health, highlights that while these drugs can be revolutionary when used appropriately, they are increasingly sought after for quick aesthetic transformations, fueled by social media and cultural pressures. The cost of treatment, ranging from ₹70,000 to ₹90,000 per month (approximately $840 to $1,080 USD), restricts access to wealthier individuals, creating shortages for patients who genuinely require these medications for managing diabetes. Misuse can lead to significant health risks, including gastrointestinal issues, dehydration, and psychological distress, with potential rebound effects after discontinuation. Furthermore, the trend of 'pre-wedding weight loss' consultations indicates a troubling shift in societal values towards body image, prioritizing rapid results over sustainable health practices. As India faces rising obesity and lifestyle diseases, there is a pressing need to balance access to these medications with responsible usage to prevent a future dominated by pharmacological dependency.